Fezolinetant and Vascular Health and Brain Health

Double-blind, placebo-controlled randomized trial to determine whether 12 weeks of 45 mg of fezolinetant, a non-hormonal treatment for hot flashes associated with menopause, improves vascular and brain health in participants with moderate to severe menopausal hot flashes. Participants will be randomized to either 12 weeks of fezolinetant 45 mg or placebo. Primary endpoints include change from baseline in endothelial function and verbal memory.